Physician profile
Susan Lynn Lamonica
NPI 1104568369
$3,316.59
in general payments reported to CMS, 2019-2025
17 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $345 · 2023: $966 · 2024: $834 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.59 | 2022-2025 | |
| Alkermes, INC. | $650.78 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $353.97 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.08 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $214.57 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $212.12 | 2023-2025 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $176.75 | 2024-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $139.96 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $118.59 | 2022-2025 | Spravato, Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $76.65 | 2023-2024 | Jornay Pm |
| Novo Nordisk INC | $51.39 | 2023-2025 | |
| Exact Sciences Corporation | $45.10 | 2023-2024 | Cologuard Collection Kit |
| Calliditas Therapeutics US INC. | $25.93 | 2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $22.76 | 2024 | Crysvita |
| Lilly USA, LLC | $20.99 | 2023 | Mounjaro, Trulicity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.82 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.54 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Lamonica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.